Evidence-Based Medicine Guidelines
Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients
Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Galactomannan in the Diagnosis of Invasive Aspergillosis in Immunocompromized Patients." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients.
Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients. Accessed May 22, 2022.
Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients
Galactomannan in the Diagnosis of Invasive Aspergillosis in Immunocompromized Patients [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2022 May 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients
ID - 452047
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452047/all/Galactomannan_in_the_diagnosis_of_invasive_aspergillosis_in_immunocompromized_patients
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
